North America Oncology Market Report

North America Oncology Market Size

The North America oncology market was valued at USD 252.44 billion in 2025, is estimated to reach USD 281.98 billion in 2026, and is projected to reach USD 683.34 billion by 2034, growing at a CAGR of 11.70% from 2026 to 2034.

MARKET DRIVERS

Rising Cancer Incidence and Aging Demographics

The increasing incidence of cancer cases, compounded by a rapidly aging population, is escalating the growth of the North American oncology market. As per the Surveillance, Epidemiology, and End Results (SEER) Program, the median age at cancer diagnosis is 66 years, with individuals aged 65 and older representing nearly 60% of all cancer diagnoses in the U.S. The U.S. Census Bureau projects that the population aged 65 and above will reach 82 million by 2030, significantly elevating cancer-related healthcare demand. Additionally, lifestyle-related risk factors such as obesity and sedentary behavior contribute to rising cancer prevalence. According to the American Cancer Society, excess body weight is responsible for about 8% of all cancer cases in the U.S. This demographic shift necessitates a surge in oncology services, including diagnostics, treatment modalities like chemotherapy and radiation therapy, and long-term survivorship care.

Technological Innovation in Cancer Treatment

The technological advancement is another factor propelling the growth of the North American oncology market, with innovations in treatment modalities such as immunotherapy, CAR-T cell therapy, and precision oncology reshaping patient outcomes. Precision oncology, supported by genomic profiling and biomarker-driven therapies, allows for personalized treatment plans that improve therapeutic accuracy and reduce adverse effects. Furthermore, the integration of artificial intelligence in diagnostic imaging enhances early detection rates, with AI-based tools achieving diagnostic accuracy rates exceeding 90% in certain cancer types, according to studies published in Nature Medicine.

MARKET RESTRAINTS

High Cost of Cancer Therapies

The escalating cost of cancer treatments, which poses a barrier to patient access and places a heavy burden on healthcare systems, is restricting the growth of the North American oncology market. According to a study published in the Journal of Clinical Oncology, the average monthly cost of newer cancer drugs ranges from $10,000 to $30,000, with some targeted therapies exceeding $150,000 annually. These high costs are driven by the complexity of drug development, limited competition in certain therapeutic areas, and the premium pricing of personalized medicines. The economic strain is further exacerbated by the rising use of combination therapies, which, while improving efficacy, significantly increase treatment expenses. A report from the American Society of Clinical Oncology (ASCO) indicates that 42% of cancer patients in the U.S. deplete their entire life savings within two years of diagnosis due to treatment-related costs. This financial toxicity not only affects patients and their families but also limits treatment adherence and outcomes.

Regulatory and Reimbursement Challenges

The regulatory complexities and inconsistent reimbursement policies is another restraint for the growth of the North American oncology market. Additionally, post-approval reimbursement challenges further hinder patient access. In the U.S., coverage decisions by Medicare and private insurers often lag behind regulatory approvals, creating a gap in treatment accessibility. According to a study by the National Pharmaceutical Council, approximately 20% of newly approved oncology drugs face delayed or restricted coverage within the first two years post-approval. Similarly, in Canada, the pan-Canadian Oncology Drug Review (pCODR) has been criticized for lengthy review timelines, with some drugs awaiting reimbursement for over two years.

MARKET OPPORTUNITIES

Expansion of Biosimilars Market

The expanding adoption of biosimilars, which offer cost-effective alternatives to high-priced biologic therapies, is anticipated to have a significant growth of the North American oncology market. As per the IQVIA Institute, biosimilar uptake in oncology has the potential to reduce treatment costs by up to 30%, translating to billions in healthcare savings annually. In 2023, the FDA had approved over 40 biosimilars, with several targeting oncology indications such as rituximab and trastuzumab. The growing acceptance among physicians and patients, coupled with supportive regulatory frameworks, positions biosimilars as a key growth driver.

Growth in Precision Oncology and Companion Diagnostics

Precision oncology, supported by companion diagnostics by enabling tailored therapeutic strategies based on individual patient tumor profiles, and is additionally to propel the growth of the North American oncology market. Companion diagnostics facilitate the identification of patients most likely to benefit from specific targeted therapies, thereby enhancing treatment efficacy and reducing unnecessary exposure to ineffective drugs. As per the National Cancer Institute, over 70% of cancer patients could potentially benefit from molecular profiling, yet only a fraction currently receive such testing. Expanding access to genomic testing and integrating it into routine clinical practice presents a substantial growth avenue. Additionally, collaborations between diagnostic companies and pharmaceutical firms to co-develop companion diagnostics are accelerating, further driving market expansion.

MARKET CHALLENGES

Workforce Shortages in Oncology

The growing shortage of specialized oncology professionals, including oncologists, radiologists, pathologists, and nurses, is hampering the growth of the North American oncology market. According to the Association of American Medical Colleges, the U.S. is projected to face a shortfall of up to 124,000 physicians by 2034, with oncology among the most affected specialties. According to the American Society of Clinical Oncology (ASCO), nearly 40% of practicing oncologists in the U.S. are aged 55 or older, raising concerns about an impending workforce crisis as retirements outpace new entrants. This shortage is further exacerbated by the increasing complexity of cancer care, which demands multidisciplinary teams and continuous training in emerging therapies. Rural and underserved areas are disproportionately affected, with limited access to oncology specialists contributing to delayed diagnoses and suboptimal treatment outcomes.

Healthcare Disparities and Access Inequities

The healthcare disparities and unequal access to oncology services is also a challenge for the growth of the North America oncology market. According to the American Cancer Society, racial and ethnic minorities, particularly African Americans, experience disproportionately higher cancer mortality rates, with a death rate 14% higher than that of non-Hispanic whites. Socioeconomic status further compounds these disparities, with individuals from lower-income households facing barriers to early detection and timely treatment. Geographic disparities are equally concerning, as rural populations often lack access to specialized oncology centers and advanced treatment modalities. A study published in the Journal of the National Cancer Institute found that rural cancer patients are 20% more likely to die from cancer than their urban counterparts, largely due to delayed diagnoses and limited treatment options.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Cancer Diagnostics & Treatment Insights

The immunotherapy segment accounted in holding 35.4% of the North American oncology market's share in 2024. This therapeutic approach has revolutionized cancer treatment by harnessing the body's immune system to combat malignancies, demonstrating remarkable efficacy across multiple cancer types. The success of immunotherapy is further evidenced by its approval expansion, with the FDA granting marketing authorization for over 40 immunotherapy agents by 2023. Healthcare providers increasingly prefer immunotherapies due to their targeted mechanism of action and reduced systemic toxicity compared to conventional chemotherapy. Additionally, the integration of immunotherapy combinations with other treatment modalities has enhanced therapeutic efficacy, driving widespread adoption. Insurance coverage expansion has also facilitated patient access, with Medicare and major private insurers covering immunotherapy treatments for approved indications.

The liquid biopsy segment is likely to grow with an expected CAGR of 18.5% throughout the forecast period. This revolutionary diagnostic technology has gained tremendous momentum due to its non-invasive nature and ability to provide real-time monitoring of tumor dynamics through circulating tumor DNA analysis. Clinical validation studies have demonstrated liquid biopsy's superior sensitivity in detecting minimal residual disease, with accuracy rates exceeding 90% in identifying circulating tumor cells and cell-free DNA fragments, according to research published in the New England Journal of Medicine. Healthcare institutions are increasingly adopting liquid biopsy for treatment monitoring and resistance detection, with major cancer centers like Memorial Sloan Kettering implementing comprehensive liquid biopsy programs. The technology's versatility extends across multiple applications, including early detection, treatment selection, and recurrence monitoring, making it invaluable in precision oncology workflows. Regulatory support has accelerated market expansion, with the FDA approving seven liquid biopsy tests for clinical use by 2023.

By Indication Insights

The lung cancer segment within the North American oncology market by indication, representing approximately 22% of the total market share with an estimated value of $26.4 billion in 2023. This dominance is primarily attributed to lung cancer's status as the leading cause of cancer-related mortality in North America, with the American Cancer Society reporting over 230,000 new cases diagnosed annually in the United States alone. The segment's substantial market presence is further reinforced by the high treatment costs associated with advanced lung cancer therapies, particularly targeted treatments and immunotherapies. Non-small cell lung cancer accounts for roughly 85% of all lung cancer cases, driving demand for sophisticated diagnostic testing and personalized treatment approaches. The economic burden of lung cancer treatment is significant, with average annual treatment costs ranging from $15,000 to $150,000 depending on disease stage and therapeutic intervention, as documented in healthcare economics studies. Insurance coverage for lung cancer screening has expanded considerably following USPSTF recommendations, with low-dose CT screening coverage reaching 78% of eligible Medicare beneficiaries by 2022, according to CMS data. The segment's growth is sustained by continuous innovation in treatment modalities, including EGFR inhibitors, ALK inhibitors, and PD-1/PD-L1 checkpoint inhibitors, which command premium pricing. Additionally, the implementation of comprehensive genomic profiling for lung cancer patients has become standard practice, generating substantial diagnostic revenue streams. The aging population demographic further supports market expansion, as lung cancer incidence increases significantly with age, with median diagnosis occurring at 70 years according to SEER statistics.

The liver cancer segment is lucratively growing with an expected CAGR of 7.8% in the coming years, with the increasing hepatitis C virus prevalence and rising obesity rates contributing to non-alcoholic fatty liver disease, which serves as a major risk factor for hepatocellular carcinoma development. Non-alcoholic fatty liver disease prevalence has surged to affect 25% of the North American population, directly correlating with the obesity epidemic that impacts over 42% of adults in the United States, according to CDC statistics. Early detection challenges contribute to the segment's growth potential, as liver cancer is frequently diagnosed at advanced stages when treatment options become limited and expensive. Combination therapy approaches integrating targeted agents with immunotherapy have demonstrated promising results, with atezolizumab plus bevacizumab achieving 40% improvement in overall survival compared to traditional sorafenib treatment in clinical trials. Healthcare system investments in liver cancer screening programs have intensified, particularly in high-risk populations, driving diagnostic procedure volumes.

By End-Use Insights

The hospitals segment was the largest and held 45.3% of the North American oncology market share in 2024, from hospitals serving as primary care delivery centers for complex cancer treatments requiring multidisciplinary expertise and advanced infrastructure. Hospital-based oncology departments typically manage the most complex cases, including patients requiring intensive care support during treatment cycles. Economic factors significantly contribute to hospital dominance, as insurance reimbursement structures favor hospital-based care for complex procedures and high-cost treatments. Medicare data indicates that hospital outpatient oncology services account for 65% of total oncology-related expenditures, highlighting the financial significance of hospital-based care.

The diagnostic laboratories segment is likely to grow with an estimated CAGR of 9.2% during the forecast perio,d with the increasing demand for specialized molecular diagnostics and companion diagnostic testing required for precision oncology applications. The segment's expansion reflects the healthcare industry's shift toward decentralized testing services, with laboratories providing specialized expertise in complex genomic profiling and biomarker analysis that may exceed hospital laboratory capabilities. Laboratory-developed tests have become increasingly important in oncology, with molecular diagnostics laboratories offering customized testing panels tailored to specific cancer types and treatment protocols. Healthcare economics favor laboratory-based testing, as specialized laboratories achieve greater economies of scale and technical expertise compared to smaller hospital-based facilities.

COUNTRY LEVEL ANALYSIS

United States Oncology Market Insights

The United States was the top performer of the North American oncology market by holding 92.3% of the share in 2024, with the advanced healthcare infrastructure, robust research ecosystem, and high healthcare expenditure levels that support premium pricing for innovative oncology treatments. The U.S. healthcare system's fragmented nature creates multiple revenue streams for oncology services, with over 1,500 cancer programs accredited by the American College of Surgeons Commission on Cancer. Healthcare spending patterns significantly favor oncology investments, with the U.S. spending nearly 18% of GDP on healthcare, substantially higher than other developed nations according to OECD health statistics. The pharmaceutical market concentration in the United States drives demand for oncology treatments, with the country representing 40% of global pharmaceutical revenues despite comprising only 4% of the world's population. Regulatory environment advantages support market growth, as the FDA's expedited approval pathways for breakthrough oncology therapies enable faster market entry compared to other regulatory bodies. Insurance coverage expansion under the Affordable Care Act increased cancer screening rates by 15% between 2010 and 2020, according to CDC health survey data.

Canada Oncology Market Insights

Canada held 8.3% of North America's oncology market share in 2024. The country's universal healthcare system creates unique market dynamics, with provincial health authorities serving as primary purchasers of oncology services and treatments. Healthcare delivery organization through provincial cancer agencies ensures standardized treatment protocols and centralized purchasing power that influences market access and pricing negotiations. The Patented Medicine Prices Review Board regulations significantly impact pharmaceutical pricing strategies, with oncology drug prices typically 20-30% lower in Canada compared to the United States, according to international pharmaceutical pricing comparisons. Population demographics support steady market growth, with Canada's aging population creating increased cancer incidence rates that drive demand for oncology services. Statistics Canada reports that cancer affects nearly 200,000 Canadians annually, with incidence rates increasing by 2% annually over the past decade. Healthcare technology adoption patterns favor evidence-based treatments, with the pan-Canadian Oncology Drug Review evaluating new oncology therapies for provincial formulary inclusion.

COMPETITIVE LANDSCAPE

The North America oncology market presents an intensely competitive landscape characterized by established pharmaceutical giants, innovative biotechnology companies, and emerging therapeutic developers vying for market dominance. Competition dynamics are shaped by rapid technological advancement, regulatory evolution, and shifting treatment paradigms that favor personalized medicine approaches. Large pharmaceutical companies leverage extensive resources, established distribution networks, and proven commercial capabilities to maintain market leadership positions while simultaneously facing pressure from agile biotechnology firms bringing disruptive innovations to market. Generic and biosimilar manufacturers create additional competitive pressures through cost-effective treatment alternatives that challenge premium pricing strategies of branded therapies. Academic medical centers and research institutions contribute to competitive intensity through translational research initiatives and early-stage therapeutic development that attract industry partnerships and licensing opportunities. Healthcare provider consolidation trends influence purchasing decisions and treatment standardization by creating winner-take-all scenarios for therapies demonstrating superior clinical outcomes and economic value propositions. Insurance coverage policies and reimbursement decisions significantly impact competitive positioning by determining treatment accessibility and market penetration rates. International market expansion strategies create additional competitive dimensions as companies seek to leverage North American regulatory approvals and clinical data for global market access.

KEY MARKET PLAYERS

Noteworthy Companies dominating the North America oncology market are

• Aegerion Pharmaceuticals Inc.
• Bristol-Myers Squibb Company
• AbbVie Inc.
• Ability Pharma
• Acadia Pharmaceuticals Inc.
• Roche Holdings AG
• Amgen Inc.
• Takeda Oncology
• Aslan Pharmaceuticals Ltd.
• Novartis AG
• Aspen Pharmacare Holdings Limited
• AstraZeneca
• Athenex, Inc.

TOP LEADING PLAYERS IN THE MARKET

• Roche has established itself as a dominant force in the North American oncology market through its comprehensive portfolio spanning diagnostics and therapeutics. The company's personalized healthcare approach integrates companion diagnostics with targeted therapies, creating synergistic value propositions that enhance treatment outcomes. Their commitment to precision medicine is evident through extensive biomarker research and development of companion diagnostic tests that guide therapeutic decisions. Roche's Genentech subsidiary has pioneered numerous breakthrough oncology treatments, while their Ventana Medical Systems division leads in tissue-based diagnostic solutions. The company's strategic focus on immuno-oncology has yielded significant market penetration through innovative checkpoint inhibitors and combination therapies. Their integrated business model seamlessly connects diagnostic capabilities with therapeutic development, enabling personalized treatment protocols that improve patient survival rates.
• Novartis has carved a distinctive position in the North American oncology market through innovative cell and gene therapy platforms alongside traditional pharmaceutical approaches. Their CAR-T cell therapy portfolio represents cutting-edge advancement in personalized cancer treatment by addressing previously untreatable hematologic malignancies with remarkable efficacy. The company's commitment to breakthrough therapies is demonstrated through substantial R&D investments focused on targeted protein degradation and novel therapeutic modalities. Novartis has successfully commercialized multiple oncology franchises, including kinase inhibitors and immunomodulatory agents that address diverse cancer types. Their strategic partnerships with academic institutions and biotechnology companies have accelerated pipeline development and market expansion. The company's digital health initiatives integrate advanced analytics and real-world evidence generation to optimize treatment outcomes and support regulatory submissions. Novartis's patient-centric approach encompasses comprehensive support programs that improve treatment accessibility and adherence. Their global manufacturing capabilities ensure reliable supply chain management for complex biologic therapies. The company's focus on combination therapies and treatment sequencing strategies has enhanced therapeutic value propositions. Novartis continues to expand its oncology footprint through strategic acquisitions and licensing agreements that complement its existing portfolio and therapeutic expertise.
• Bristol-Myers Squibb has emerged as a prominent player in the North American oncology market through pioneering immunotherapy research and strategic portfolio expansion. Their immune checkpoint inhibitor platform has revolutionized cancer treatment paradigms, particularly in melanoma, lung cancer, and hematologic malignancies. The company's research excellence in immuno-oncology has yielded multiple approved therapies that demonstrate superior efficacy compared to traditional treatment approaches. Strategic acquisitions have significantly strengthened their pipeline and market position, enabling rapid expansion into novel therapeutic areas and treatment modalities. Their commitment to combination therapy development has enhanced treatment outcomes while creating sustainable competitive advantages through intellectual property protection. Bristol-Myers Squibb's collaborative research initiatives with leading academic institutions and cancer centers have accelerated innovation and clinical development timelines. The company's global manufacturing infrastructure supports complex biologic production requirements while ensuring regulatory compliance across multiple jurisdictions.

TOP STRATEGIES USED BY KEY MARKET PARTICIPANTS

Leading pharmaceutical companies in the North American oncology market actively pursue strategic partnerships with biotechnology firms, academic institutions, and diagnostic companies to accelerate innovation and expand their therapeutic pipelines. These collaborations enable resource sharing, risk mitigation, and access to specialized expertise that might otherwise be unavailable internally. Companies form joint ventures to co-develop companion diagnostics alongside therapeutic agents, ensuring seamless integration of personalized medicine approaches. Academic partnerships facilitate early-stage research translation into commercial applications while providing access to cutting-edge scientific discoveries. Technology collaborations with artificial intelligence companies enhance drug discovery capabilities and improve clinical trial design efficiency. These strategic alliances also enable market expansion into emerging therapeutic areas and geographical regions where partner organizations possess established expertise and infrastructure.

Key market players focus extensively on diversifying their oncology portfolios across multiple therapeutic modalities including small molecules, biologics, cell therapies, and combination treatments. This approach reduces dependency on single therapeutic platforms while creating multiple revenue streams and competitive advantages. Companies invest significantly in expanding indications for existing therapies through additional clinical trials and regulatory submissions. Pipeline diversification strategies encompass various cancer types and treatment mechanisms to address unmet medical needs across the oncology spectrum. Geographic expansion through regulatory filings in multiple jurisdictions ensures maximum market penetration and revenue optimization. Companies also pursue lifecycle management strategies for mature products through formulation improvements, delivery system enhancements, and new indication approvals.

Major oncology market participants increasingly integrate digital technologies and data analytics into their business operations to enhance research capabilities, improve patient outcomes, and optimize commercial strategies. Artificial intelligence applications accelerate drug discovery processes, improve clinical trial design, and enhance patient selection for personalized treatments. Real-world evidence generation through electronic health record analysis and patient registries supports regulatory submissions and market access negotiations. Digital health platforms facilitate patient monitoring, treatment adherence, and outcome tracking while reducing healthcare system costs. Companies invest in telemedicine capabilities and remote patient monitoring technologies to expand care delivery models and improve treatment accessibility. Data analytics capabilities enable precision medicine approaches through genomic profiling integration and treatment response prediction modeling. These technological investments also support supply chain optimization, manufacturing efficiency improvements, and quality control enhancement throughout the product lifecycle.

RECENT MARKET DEVELOPMENTS

• In March 2024, Roche announced the launch of its next-generation sequencing platform for comprehensive genomic profiling, expanding its companion diagnostic capabilities to support personalized cancer treatment decisions across multiple tumor types.
• In January 2024, Novartis completed the acquisition of Chinook Therapeutics, strengthening its oncology pipeline with novel targeted therapies for hematologic malignancies and solid tumors through enhanced drug development capabilities.
• In November 2023, Bristol-Myers Squibb entered into a strategic collaboration with Tempus Labs to integrate artificial intelligence-driven genomic analysis into clinical trial design and patient selection processes for immuno-oncology treatments.
• In August 2023, Merck & Co. received FDA approval for its PD-1 inhibitor combination therapy for first-line treatment of advanced gastric cancer by expanding its oncology portfolio and market reach in gastrointestinal malignancies.
• In May 2023, Pfizer announced a partnership with IBM Watson Health to develop artificial intelligence applications for oncology drug discovery and clinical trial optimization by enhancing its digital transformation initiatives in cancer treatment development.

MARKET SEGMENTATION

This North America oncology market research report is segmented and sub-segmented into the following categories.

By Cancer Diagnostics & Treatment

• Cancer Diagnostics
  • Biopsy
  • Imaging
  • Immunohistochemistry
  • Tumor Biomarkers Test
  • In Situ Hybridization
  • Liquid Biopsy
• Cancer Treatment
  • Targeted Therapy
  • Chemotherapy
  • Hormonal Therapy
  • Immunotherapy
  • Others

By Indication

• Lungs Cancer
• Colorectal Cancer
• Breast Cancer
• Liver Cancer
• Bladder Cancer
• Head & Neck Cancer
• Prostate Cancer
• Others

By End-use

• Hospitals
• Diagnostic laboratories
• Diagnostic imaging centers
• Academia
• Specialty clinics
• Others

By Country

• United States
• Canada
• Mexico
• Rest of North America